The relationship between the occurrence of retinal vein occlusion disease and blood composition

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041414

Enrollment

Unknown

Registered

2020-12-25

Start date

2020-08-24

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

retinal vein occlusion disease group vs normal control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old. 2. Patients who have not used drugs or surgery. 3. Patients whose onset time is less than 2 weeks. 4. The patients who have no influence on fundus examination and whose pupil can be dilated by more than 6 mm can meet the requirements of fundus thorough examination. 5. Patients who signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other eye diseases affecting the determination of experimental results. 2. Patients with serious influence on blood composition, such as leukemia, coronary heart disease, upper respiratory tract infection, obesity, pregnancy status, etc. 3. Patients who have used drugs affecting blood composition in the past 3 months (except oral drugs used for the treatment of the disease). 4. Patients who are unable to cooperate or have mental disorders. 5. Patients who had undergone surgery (including anti VEGF therapy) within one month.

Design outcomes

Primary

Measure	Time frame
Platelet function;Platelet count;DIC set;TAT, TM, PIC, t-PAIC;	—

Countries

China

Contacts

Public ContactLu Peirong

The First Affiliated Hospital of Suzhou University

lupeirong@suda.edu.cn+86 13914083528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026